Jaguar Health Q2 2026 Financial Results Overview

Jaguar Health, Inc. released its second-quarter 2026 financial results, highlighting its focus on advancing crofelemer for rare intestinal failure diseases. A presentation at ESPGHAN 2026 showcased crofelemer reducing parenteral support in pediatric patients with microvillus inclusion disease. Jaguar plans to submit an NDA for MVID by Q2 2027.

The company's license and grant revenue remained consistent, with $43,000 recognized from a European partnership, while prescription product revenue was $1.2 million, a 60% decline from Q2 2025. Net revenue dropped by 59% overall, attributed to decreased product sales and the Future Pak licensing agreement.

Operational losses decreased slightly to $7.6 million. However, net loss increased to $12.7 million due to higher interest expenses and losses on extinguishment of debt. Jaguar continues to work on the crofelemer powder formulation for rare-disease clinical trials.